What I have: vomiting · semaglutide · STEP 1.
This is presented as though it settles something, and I am not convinced it does.
I have two documents that appear to disagree, which is what prompted this.
What is the correct interpretation, and what is the common misreading?
Take it from the STEP 1 adverse-event table by arm, and check the unit before you use it. An incidence can be the proportion of participants who reported the event at least once, or the count of events divided by exposure time, and the two differ by however many people had it repeatedly. Then subtract the placebo arm, because the untreated rate is not zero. And read the discontinuation column beside it: an event that made people leave the trial is under-counted at every later visit, so a low late-timepoint incidence can mean the event was severe rather than rare.
Answer first: vomiting is less common than nausea, is more strongly dose-related, and matters chiefly because of what it does to fluid and electrolyte balance.
Oral rehydration solutions work by glucose-coupled sodium co-transport, which continues to function when secretion is deranged. That is why the glucose-to-sodium ratio matters and a high-sugar sports drink is not equivalent.
Stated carefully, a practical home formulation is about six level teaspoons of sugar and half a level teaspoon of salt in one litre of water, taken in small frequent sips rather than in volumes that provoke another episode.
Vomiting rates in the trial programmes are reported separately from nausea and are consistently lower and more dose-dependent.
Anti-emetics interact with other medication and are a prescriber decision.
The renal risk here is volume, not toxicity. That is the mechanism to watch.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe honest answer is that a day of it is unpleasant and that several days of it needs help.
Trial incidence for vomiting runs at roughly a third to a half of the nausea rate depending on agent and dose, and it is more concentrated in the escalation phase than nausea is.
An episode of vomiting several days after a dose, with no escalation and no other explanation, is not the typical pattern and deserves attention rather than tolerance.
Oral rehydration solution composition is standardised by the World Health Organization and rests on glucose-coupled sodium transport.
If fluids will not stay down for several hours, that is the threshold. Get help.
The short version: usually escalation-related, usually self-limiting, and dangerous mainly through dehydration.
Warning signs that convert this from a nuisance to a clinical problem: inability to keep fluids down for more than a few hours, reduced urine output, dizziness on standing, confusion, or severe abdominal pain.
Stated carefully, dental enamel erosion from repeated vomiting is a real if unglamorous consequence; rinsing with water rather than brushing immediately is the standard advice.
Research-use material is not approved for human use, and an unverified dose is an unquantifiable variable in any of this.
Rinse rather than brush after an episode. Enamel is not replaceable.
Answering this needs to know whether fluids are being kept down, since that is the threshold between manageable and clinical.
Repeated vomiting is the mechanism behind most reported acute kidney injury in this class. The renal event is a volume event, not a direct toxicity.
The caveat is that persistent vomiting is a clinical situation and this is not the place to manage one.
Do not escalate the dose while this is happening.
edited 4 Feb 2025 by tabular_nums — added a caveat about sampling
Specifically, this is the adverse effect where the honest advice is least about tolerance and most about knowing when to stop.
Fluid lost in vomit carries sodium at roughly 60 millimoles per litre and potassium at rather less, so replacing it with plain water alone dilutes plasma sodium rather than restoring balance.
Electrolyte composition of gastric and intestinal secretions is published and is the basis for replacement calculations.
Small frequent sips of an oral rehydration solution, not large volumes of water.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.